Novartis (NYSE:NVS) executives outlined a slate of upcoming drug-trial results and regulatory discussions across immunology, cardiovascular disease, oncology and neuroscience, while reiterating sales ambitions for several established medicines.
Among the company’s priorities are securing a label fo